Probe: Alzheimer’s Drug Approval ‘Rife With Irregularities’

Probe: Alzheimer’s Drug Approval ‘Rife With Irregularities’
FILE - A sign for the Food and Drug Administration is displayed outside its offices in Silver Spring, Md., on Dec. 10, 2020. The FDA’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday, Dec. 29, 2022, as congressional investigators called the process “rife with irregularities.” (AP Photo/Manuel Balce Ceneta, File)

WASHINGTON (AP) — The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.”

The 18-month investigation by two House committees detailed “atypical collaboration” between FDA regulators and a company it’s supposed to oversee — Aduhelm manufacturer Biogen. The probe also cited Biogen documents saying the company intended to “make history” when it set what investigators called an “unjustifiably high” initial price of $56,000 a year for the drug.

The criticism comes as the FDA is expected to decide whether to approve another new Alzheimer’s drug in January. Thursday’s report urged the agency to “take swift action” to ensure that any future Alzheimer’s approvals aren’t met with “the same doubts about the integrity of FDA’s review.”

The FDA and Biogen issued statements Thursday defending the Aduhelm approval process.

In 2021, the FDA overruled its own independent scientific advisers when it approved Aduhelm even though research studies failed to prove it really helped patients. Biogen had halted two studies after disappointing results suggested the drug wasn’t slowing Alzheimer’s inevitable worsening — only to later contend that a new analysis of one study showed higher doses offered an incremental benefit.

The FDA argued the drug’s ability to reduce a hallmark of Alzheimer’s, a buildup of plaque in the brain, suggested it was likely to slow the disease. Backlash was immediate as three FDA advisers resigned in protest and the agency’s then-acting chief called for an internal investigation. Eventually Medicare refused to pay for the drug — even after the yearly price was dropped to $28,000 — unless patients enrolled in clinical trials to prove if it indeed slowed cognitive decline.

Thursday’s report said FDA and Biogen engaged in an unusually high volume of phone calls, meetings and emails, some of them not properly documented. In addition, the regulators and company spent months working together to prepare a briefing document for FDA’s advisers that didn’t adequately represent substantial disagreement within the FDA about how to handle Aduhelm, the report said.

The investigators recommended that FDA take steps to restore trust in the approval process that include properly documenting interactions with drugmakers. They also urged manufacturers to take into account advice from patient groups and other outside experts on fair drug pricing.

In a statement Thursday, FDA said the Aduhelm decision “was based on our scientific evaluation of the data” and that the agency’s own internal review found its interactions with Biogen were appropriate. But it said it plans to update guidance on Alzheimer’s drug development and will review the investigation’s findings.

In its own statement, Biogen said: “Alzheimer’s is a highly complex disease and we have learned from the development and launch of Aduhelm” but that it “stands by the integrity of the actions we have taken.”

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

A+
a-
  • Biogen
  • FDA
  • In The News

    Health

    Voting

    Health

    Anthony Fauci to Testify Before Congress on COVID Origins and US Pandemic Response

    WASHINGTON (AP) — Anthony Fauci, former chief White House medical adviser, is expected to testify before Congress early next year... Read More

    WASHINGTON (AP) — Anthony Fauci, former chief White House medical adviser, is expected to testify before Congress early next year as part of Republicans' yearslong investigation into the origins of COVID-19 and the U.S. response to the disease. Fauci, who served as the nation's top infectious... Read More

    November 29, 2023
    by Tom Ramstack
    Congress Confronted With Pros and Cons of Health Care AI

    WASHINGTON — A congressional committee took a cautious step Wednesday into the prospects for artificial intelligence to improve health care.... Read More

    WASHINGTON — A congressional committee took a cautious step Wednesday into the prospects for artificial intelligence to improve health care. The benefits could be great but so could the risks to privacy, according to medical personnel who testified before a House Energy and Commerce subcommittee. “It... Read More

    November 29, 2023
    by Jesse Zucker
    Guide to Preparing Healthy Meals for the Work Week

    WASHINGTON — When you’re always on the go it’s hard to find the time to prepare healthy meals. There’s nothing... Read More

    WASHINGTON — When you’re always on the go it’s hard to find the time to prepare healthy meals. There’s nothing wrong with grabbing some meals out, but the financial and health costs can add up. Eating homemade, healthy, balanced meals fuels your body and brain and... Read More

    November 28, 2023
    by Tom Ramstack
    Senate Considers Public Health Strategy to Control Rising Gun Violence

    WASHINGTON — Perplexing problems of gun violence returned to a Senate hearing Tuesday, this time with a proposal for treating... Read More

    WASHINGTON — Perplexing problems of gun violence returned to a Senate hearing Tuesday, this time with a proposal for treating it as a public health crisis rather than purely a law enforcement issue. A near record surge in violence has resulted in more than 38,000 Americans... Read More

    November 28, 2023
    by Dan McCue
    Maryland Expands Access to Contraceptive Care

    ANNAPOLIS, Md. — The state of Maryland has entered into a four-year partnership with a Boston, Massachusetts-based nonprofit to eliminate... Read More

    ANNAPOLIS, Md. — The state of Maryland has entered into a four-year partnership with a Boston, Massachusetts-based nonprofit to eliminate barriers to contraceptive care. In an announcement on Tuesday, Gov. Wes Moore said the cooperative agreements between the Maryland Department of Health and Upstream USA will... Read More

    Mayo Clinic Announces $5B Expansion of Minnesota Campus

    MINNEAPOLIS (AP) — The Mayo Clinic announced a $5 billion expansion plan for its flagship campus Tuesday that includes new... Read More

    MINNEAPOLIS (AP) — The Mayo Clinic announced a $5 billion expansion plan for its flagship campus Tuesday that includes new buildings designed so they can evolve and expand as patient needs change over the coming decades. The project is part of a Mayo strategy to transform... Read More

    News From The Well
    scroll top